Seeking Alpha analyst and Investing Group leader, Manika Premsingh believes the worst is now behind GSK, adding that even though there is risk to core EPS growth of forecasts 10-12% for the full ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Zantac may have been a heartburn medicine but it caused one almighty headache for GSK chief executive Emma ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK GSK0.31%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim. Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could ...

GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

GSK GSK1.94%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...

GSK cuts 2024 vaccine sales forecast for second ... compared with estimates of 43.6 pence on sales of about 8 billion pounds. It kept full-year total sales and earnings forecasts unchanged.

(Alliance News) - GSK PLC on Tuesday said its Arexvy treatment ... cumulative efficacy over three full RSV seasons was clinically meaningful. "These results include efficacy against different ...